Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Airlines Group Inc (AAL) vs AstraZeneca plc (AZN) Price & Performance

American Airlines Group IncTrade
AstraZeneca plcTrade

Price performance (Past 24H)

Key statistics

American Airlines Group Inc vs AstraZeneca plc — how do they compare? American Airlines Group Inc trades at $15.02 (market cap $10.55B), while AstraZeneca plc trades at $158.41 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 23.5× American Airlines Group Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while American Airlines Group Inc pays none. Which is the better fit depends on your goals.

AALAZN
Market Cap
$10.55B$248.14B
Sector
IndustrialsHealth
52-Week High
$18.15$209.48
52-Week Low
$10.18$147.06
Enterprise Value
$38.51B$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Airlines Group Inc

American Airlines (AAL) trades at $14.94, down 0.43% with a bearish technical signal. The company shows mixed fundamentals with strong revenue growth but negative net income margin (-0.56%) and elevated P/E of 43.73. Recent Q2 2026 earnings beat expectations with $0.15 EPS versus $0.03 expected, while Q4 2025 missed estimates. Cash flow remains positive with $154M net cash flow in 2025. Analyst consensus is mixed with 44.7% buy ratings and $19.63 price target, representing 31% upside.

AAL presents a turnaround opportunity with premium revenue growth and debt reduction, but faces significant headwinds from fuel costs and negative equity. The stock trades below analyst targets but requires sustained profitability improvement to justify current valuation multiples. Key risks include fuel price volatility and competitive pressure in the airline industry.

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Airlines Group Inc

American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.

Read more on AAL

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN